2月25日，柳药集团跌0.06%，成交额1.14亿元。两融数据显示，当日柳药集团获融资买入额1881.74万 元，融资偿还2949.09万元，融资净买入-1067.35万元。截至2月25日，柳药集团融资融券余额合计4.30 亿元。 融资方面，柳药集团当日融资买入1881.74万元。当前融资余额4.30亿元，占流通市值的6.01%，融资余 额低于近一年10%分位水平，处于低位。 融券方面，柳药集团2月25日融券偿还3300.00股，融券卖出100.00股，按当日收盘价计算，卖出金额 1801.00元；融券余量2.43万股，融券余额43.76万元，低于近一年30%分位水平，处于低位。 资料显示，广西柳药集团股份有限公司位于广西壮族自治区柳州市官塘大道68号，成立日期1981年12月 23日，上市日期2014年12月4日，公司主营业务涉及医药批发、医药零售和医药工业。主营业务收入构 成为：批发78.16%，零售15.95%，工业5.47%，其他(补充)0.42%。 分红方面，柳药集团A股上市后累计派现17.89亿元。近三年，累计派现7.20亿元。 机构持仓方面，截止2025年9月30日，柳药集团十大流通股东中，香港 ...

证券代码：603368 证券简称：柳药集团 公告编号：2026-007 一、担保情况概述 （一）担保的基本情况 2026 年 1 月，为支持广西柳药集团股份有限公司（以下简称"公司"）下属 控股子公司的生产经营和业务发展需要，公司就下属控股子公司向银行申请综合 授信等事项合计新增 20,000 万元的担保，同时解除担保金额合计 24,722.33 万元。 2026 年 1 月，公司为下属控股子公司提供担保的具体情况如下： 广西柳药集团股份有限公司 关于为下属控股子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 大药房"） | | 广西桂中大药房连锁有限责任公司（简称"桂中 | | --- | --- | --- | --- | --- | | 担保 | 本次担保金额 | 20,000.00 | 万元 | | | 对象 | 实际为其提供的担保余额 | 48,000.00 | 万元（含本次） | | | | 是否在前期预计额度内 | 是 | □ ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 截至2026年1月31日，公司通过集中竞价交易方式回购股份数量为1,080.30万股，已回购股份占公司目前 总股本的比例为2.72%，较上次回购进展公告披露数相比无变化，回购成交的最高价为19.07元/股、最 低价为17.83元/股，已支付的总金额为19,863.82万元（不含交易费用）。 特此公告。 广西柳药集团股份有限公司董事会 2026年2月3日 一、回购股份的基本情况 广西柳药集团股份有限公司（以下简称"公司"）于2025年7月25日召开第五届董事会第二十七次会议， 审议通过了《关于以集中竞价交易方式回购股份方案的议案》，同意公司使用自有资金和自筹资金通过 集中竞价交易方式回购部分公司A股股份，在未来适宜时机用于实施股权激励及/或员工持股计划。本次 回购资金总额不低于人民币10,000万元（含），不超过人民币20,000万元（含）；回购价格上限不超过 人民币25.70元/股（含）；回购期限为自董事会审议 ...

证券日报网讯2月2日，柳药集团（603368）发布公告称，截至2026年1月31日，公司通过集中竞价交易 方式回购股份数量为1，080.30万股，已回购股份占公司目前总股本的比例为2.72%。 ...

Group 1 - The core point of the article is that Liu Pharmaceutical Group (603368.SH) has announced a share buyback program, with a total of 10.803 million shares repurchased, representing 2.72% of the company's total share capital as of January 31, 2026 [1] - The highest price for the repurchased shares was 19.07 yuan per share, while the lowest price was 17.83 yuan per share [1] - The total amount paid for the repurchase, excluding transaction fees, was 199 million yuan [1]

Group 1 - The company, Liu Pharmaceutical Group (603368.SH), announced a share buyback program, with a total of 10.803 million shares repurchased as of January 31, 2026, representing 2.72% of the company's total share capital [1] - The highest price for the repurchased shares was 19.07 CNY per share, while the lowest price was 17.83 CNY per share [1] - The total amount paid for the repurchase, excluding transaction fees, was 199 million CNY [1]

证券代码：603368 证券简称：柳药集团 公告编号：2026-006 广西柳药集团股份有限公司 关于以集中竞价交易方式股份回购的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/7/26 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 7 月 7 | 25 | 日~2026 | 年 | 月 | 24 日 | | 预计回购金额 | 10,000万元~20,000万元 | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 1,080.30万股 | | | | | | | 累计已回购股数占总股本比例 | 2.72% | | | | | | | 累计已回购金额 | 19,863.82万元 | | | | | ...

Group 1 - The core point of the news is that Guangxi Liuyuan Group Co., Ltd. won a procurement project from the Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital, with a bid amount of 4.76 million yuan [1][2] Group 2 - In 2024, the company's operating revenue was 21.182 billion yuan, with a growth rate of 1.78% [2] - The net profit attributable to the parent company for 2024 was 855 million yuan, with a growth rate of 0.62% [2] - The return on equity was 11.62% [2] - In the first half of 2025, the company's operating revenue was 10.301 billion yuan, with a decline of 3.21% [2] - The net profit attributable to the parent company for the first half of 2025 was 429 million yuan, with a decline of 7.52% [2] Group 3 - The company operates in the daily consumer industry, with main product types including biological diagnostic reagents, organic chemical pesticides, diagnostic treatment equipment, and traditional Chinese medicine pieces [2] - The main business composition in 2024 was: pharmaceuticals 85.41%, medical devices 13.45%, others 0.74%, and other businesses 0.4% [2]

Group 1 - On January 23, Liuyao Group's stock increased by 1.57%, with a trading volume of 275 million yuan [1] - The financing data shows that on the same day, Liuyao Group had a financing purchase amount of 28.11 million yuan and a financing repayment of 44.46 million yuan, resulting in a net financing outflow of 16.35 million yuan [1] - As of January 23, the total balance of margin trading for Liuyao Group was 451 million yuan, which accounts for 6.07% of its circulating market value, indicating a low level compared to the past year [1] Group 2 - As of September 30, Liuyao Group had 30,400 shareholders, a decrease of 7.62% from the previous period, while the average circulating shares per person increased by 8.25% to 13,050 shares [2] - For the period from January to September 2025, Liuyao Group reported an operating income of 15.758 billion yuan, a year-on-year decrease of 1.47%, and a net profit attributable to shareholders of 646 million yuan, down 9.81% year-on-year [2] - Since its A-share listing, Liuyao Group has distributed a total of 1.789 billion yuan in dividends, with 720 million yuan distributed over the past three years [2]

Core Viewpoint - The announcement details the maturity and repayment results of the "Liuyao Convertible Bonds," including conversion statistics and the impact on the company's financial structure [1][3][4]. Group 1: Issuance and Maturity Overview - The company issued 8,022,000 convertible bonds with a total value of 800.22 million yuan, with a maturity period from January 16, 2020, to January 15, 2026 [2]. - The bonds were listed on the Shanghai Stock Exchange starting February 24, 2020, under the name "Liuyao Convertible Bonds" and code "113563" [2]. Group 2: Conversion and Repayment Details - As of January 15, 2026, a total of 1,222,000 yuan worth of bonds were converted into 55,677 shares, representing 0.0154% of the total shares before conversion [3]. - The total number of bonds due for repayment is 8,009,780, with a total repayment amount of 865,056,240 yuan, scheduled for January 16, 2026 [4][5]. Group 3: Financial Impact and Share Capital Changes - The conversion of bonds increased the company's total share capital by 55,677 shares, which may dilute earnings per share in the short term but will not affect governance or ongoing operations [6][7]. - The company maintains a healthy financial status and normal cash flow, indicating that the bond repayment will not impact daily operations [6][7]. Group 4: Taxation Policy for Non-Resident Enterprises - From January 1, 2026, to December 31, 2027, interest income from bonds held by foreign institutions will be temporarily exempt from corporate income tax and value-added tax, benefiting non-resident enterprises [8].